Principal Investigator, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital
Director of the Clinical and Translational Research Program, MGH Heart Center
Associate Professor of Medicine, Harvard Medical School
Senior Associate, Broad Institute of Harvard and MIT
Dr. Gerszten’s research efforts focus on understanding the molecular basis of injury responses in cardiovascular disease. His laboratory has incorporated emerging proteomics and metabolomics technologies to help identify novel signals derived from leukocytes, endothelial cells, or from the myocardium. In ongoing translational studies, his group applies these same methodologies directly to samples from well-phenotyped human cohorts to identify candidate biomarkers, returning again to the bench to define functional roles. The research incorporates basic molecular and cell biology, chemistry and mass spectrometry, bioinformatics, all with a foundation in clinical medicine. The overall goal is to identify new metabolites and proteins that mark cardiovascular disease activity, shed insight into disease progression, and provide targets for therapeutic intervention.
A study led by Robert Gerszten, MD, director of clinical and translational research at the Massachusetts General Hospital Institute for Heart, Vascular and Stroke Care, identifies a biomarker that can predict diabetes risk.
Hours: Mon-Fri 8:30am-5pm
Public Transportation Access: yes
Disabled Access: yes
Administrative Assistant - Colleen Squires
Laboratory Manager - Sumita Sinha, PhD